Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) received a $23.00 price target from investment analysts at Piper Jaffray Companies in a report issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 43.75% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. Oppenheimer Holdings, Inc. set a $21.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $21.22.

Shares of Vanda Pharmaceuticals (VNDA) traded down 3.61% during trading on Thursday, hitting $16.00. 534,501 shares of the company’s stock were exchanged. Vanda Pharmaceuticals has a 12-month low of $11.58 and a 12-month high of $18.00. The company has a 50-day moving average of $15.89 and a 200-day moving average of $14.60. The company’s market cap is $715.49 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.88%. The firm had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities analysts expect that Vanda Pharmaceuticals will post ($0.61) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) PT Set at $23.00 by Piper Jaffray Companies” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/05/vanda-pharmaceuticals-inc-vnda-pt-set-at-23-00-by-piper-jaffray-companies.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc raised its position in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL bought a new position in shares of Vanda Pharmaceuticals during the first quarter valued at $193,000. Capital Fund Management S.A. bought a new position in shares of Vanda Pharmaceuticals during the first quarter valued at $195,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Vanda Pharmaceuticals during the first quarter valued at $196,000. Finally, AQR Capital Management LLC bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $223,000. 91.35% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.